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Abstract
Purpose: The purpose of this study was to clarify the prognostic significance of lymphocyte infiltration in soft tissue
sarcomas (STS). Prognostic markers in potentially curable STS should guide therapy after surgical resection. The immune
status at the time of resection may be important, but the prognostic significance of tumor infiltrating lymphocytes is
controversial as the immune system has conflicting roles during cancer development.
Experimental Design: Tissue microarrays from 249 patients with STS were constructed from duplicate cores of viable and
representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the CD3+, CD4+, CD8+, CD20+ and
CD45+ lymphocytes in tumors.
Results: In univariate analyses, increased numbers of CD4+ (P=0.008) and CD20+ (P=0.006) lymphocytes in tumor
correlated significantly with an improved disease-specific survival (DSS) in patients with wide resection margins (n=108). In
patients with non-wide resection margins (n=141) increased numbers of CD3+ (P=0.028) lymphocytes in tumor correlated
significantly with shorter DSS. In multivariate analyses, a high number of CD20+ lymphocytes (HR=5.5, CI 95% =1.6–18.6,
P=0.006) in the tumor was an independent positive prognostic factor for DSS in patients with wide resections margins.
Conclusions: High density of CD20+ lymphocytes in STS with wide resection margins is an independent positive prognostic
indicator for these patients. Further research is needed to define if CD20+ cells can modify tumors in a way that reduces
disease progression and metastatic potential.
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Introduction
Soft tissue sarcomas (STS) are relatively rare, heterogeneous
malignancies of mesenchymal origin with a high mortality rate.
They comprise less than 1% of adult malignancies[1] and
approximately 50% of the STS patients will succumb to their
disease because of metastasis or local relapse[2]. There are several
prognostic factors which determine tumour progression, and
ultimately the patient’s outcome, including positive resection
margins; presence of local recurrence; and tumour grade, size,
location, depth and histological entity[3–9].
Many studies have been designed to investigate the prognostic
factors of STS by using immuno-histochemical methods[10]. Most
of the published data have focused on the expression of markers
for cell kinetics and regulatory proteins of the cell cycle.
Tumor infiltrating lymphocytes are considered to be an
indication of the host immune reaction to tumor antigens[11],
and their clinical significance has been reported in a variety of
human solid tumors.
CD3 is a part of the T cell receptor (TCR) complex on a mature
T lymphocyte. CD4 is a glycoprotein expressed on the surface of T
helper cells, regulatory T cells, monocytes, macrophages, and
dendritic cells. CD8 is a transmembrane glycoprotein that serves
as a co-receptor for the T cell receptor (TCR). Like the TCR,
CD8 binds to a major histocompatibility complex (MHC)
molecule, but is specific for the class I MHC protein. CD20 is a
non-glycosylated phosphoprotein expressed on the surface of all
mature B-cells. CD20 is expressed on all stages of B cell
development except the first and last; it is present from pre-pre
B cells through memory cells, but not on either pro-B cells or
plasma cells. The CD45 antigen was originally called leukocyte
common antigen. The protein encoded by this gene is a member
of the protein tyrosine phosphatase (PTP) family. This gene is
specifically expressed in hematopoietic cells. This PTP has been
shown to be an essential regulator of T- and B-cell antigen
receptor signalling (http://www.genecards.org).
The purpose of this study was to clarify the prognostic
significance of lymphocyte infiltration in non-gastrointestinal
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expression of CD3+, CD4+, CD8+, CD20+ and CD45+
lymphocytes in 249 patients with non-GIST STS in relation to
other clinicopathological variables.
Materials and Methods
Patients and Clinical Samples
The National Cancer Data Inspection Board and The Regional
Committee for Research Ethics approved the study. The Regional
Committee approved that written consent from the patients for
their information to be stored in the hospital database and used for
research was not needed. This because most of the material was
more than 10 years old, and most of the patients being dead. The
material was collected from our approved biobank for paraffin
embedded material and slides. Data were analyzed anonymously.
Primary tumor tissues from patients diagnosed with STS at the
University Hospital of North Norway (UNN) from 1973 to 2006
and the Hospitals of Arkhangelsk region, Russia, were used in this
retrospective study. 496 potentially suitable patient records were
identified from the hospital database but only 249 of these were
eligible for this study because they had complete medical records
and adequate paraffin-embedded tissues blocks. This report
includes follow-up data for 167 Norwegian patients and 82
Russian patients up to September 2009. The median follow-up
was 38 (range 0–392) months. Complete demographic and clinical
data were collected retrospectively. Formalin-fixed and paraffin-
embedded tumor specimens were obtained from the archives of
the Departments of Pathology at UNN and Archangelsk. The
tumors were graded according to the French Fe `de `ration
Nationales des Centres de Lutte Contre le Cancer (FNCLCC),
[WHO Tumors of Soft Tissue and bone, 2002]. Wide resection
margins were defined as wide local resection with free microscopic
margins or amputation of the affected limb or organ. Non-wide
resection margins were defined as either marginal or intralesional
resection margins, or no surgery.
Microarray construction
The histology of all soft tissue sarcoma cases were reviewed by
two pathologists (AV and SWS). Tissue microarrays (TMAs) were
constructed for high-throughput molecular pathology re-
search[12]. The most representative areas of viable tumor cells
Figure 1. IHC microscopic pictures of TMA of soft tissue sarcoma representing different scores for CD4+ and CD20+ lymphocytes.
(A) CD4 low score; (B) CD4 high score; (C) CD20 low score; (D) CD20 high score. Original magnification X 400.
doi:10.1371/journal.pone.0014611.g001
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log rank test), N=249.
Characteristic
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%) P
Age
#20 years 20 8 15 40 0.126
21–60 years 113 45 68 52
.60 years 116 47 30 40
Gender
Male 110 44 41 46 0.390
Female 139 56 45 45
Nationality
Norwegian 167 67 63 51 0.011
Russian 82 33 22 34
Histology
Undifferentiated
pleomorphic sarcoma
68 27 29 40 0.102
Leiomyosarcoma 67 27 45 46
Liposarcoma 34 14 NR 67
MF/MFT 20 8 43 50
Angiosarcoma 13 5 10 31
Rhabdomyosarcoma 16 6 17 38
MPNST 11 4 49 45
Synovial sarcoma 16 6 31 29
Other STS 4 2 NR 75
Tumor localization
Extremities 89 36 100 53 0.348
Trunk 47 29 32 44
Retroperitoneum 37 25 25 38
Head/Neck 18 7 15 41
Visceral 58 23 30 42
Tumor size
#5 cm 74 30 127 57 0.027
5–10 cm 91 37 44 45
.10 cm 81 32 28 37
Missing 3 1
Malignancy grade FNCLCC
16 1 2 5 N R 7 4 ,0.001
29 8 3 9 4 1 4 5
39 0 3 6 1 6 2 6
Tumor depth
Superficial 17 7 NR 93 ,0.001
Deep 232 93 36 42
Metastasis at time of diagnosis
No 206 83 76 53 ,0.001
Yes 43 17 10 10
Surgery
Yes 228 92 59 50 ,0.001
No 21 8 5 0
Surgical margins
Wide 108 43 NR 62 ,0.001
Impact of Lymphocytes in STS
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(HE) slides for the corresponding donor blocks and sampled for the
tissue microarray collector blocks. The TMAs were assembled
using a tissue-arraying instrument (Beecher Instruments).
Studies suggest that punching multiple 0.6 mm cores from
different regions captures the heterogeneity of the tumors more
accurately than single 2 to 4 mm core[13]. Hence, we chose using
two 0.6-mm cores of viable neoplastic tissue that were selected to
be as representative as possible (different areas), after reviewing all
original sections of the tumor and taking the heterogeneity in
consideration. To include all core samples, 12 tissue array blocks
were constructed. Multiple 4-mm sections were cut with a Micron
microtome (HM355S) and stained by specific antibodies for
immunohistochemistry (IHC).
Immunohistochemistry (IHC)
The applied antibodies were subjected to in-house validation
by the manufacturer for IHC analysis on paraffin-embedded
material. Ventana Benchmark, XT automated slide stainer
(Ventana Medical System, France) was used for IHC. Sections
were deparaffinized with xylene and rehydrated with ethanol.
Antigen retrieval was performed by placing the specimens in
0.01 M citrate buffer at pH 6.0 and exposing them to two
repeated microwave heatings of 10 minutes each at 450W. The
DAKO Envision+ System-HRP (DAB) kit was used as endogen
peroxidase blocking. As negative staining controls, the primary
antibodies were replaced with the primary antibody diluents.
Primary mouse monoclonal antibodies were incubated for 16
minutes (CD20, clone L26 Ventana), 20 minutes (CD4, clone 1F6
Novocastra, dilution 1:5) and 32 minutes (CD8, clone 1A5
Ventana) at room temperature. The Ventana antibodies were
pre-diluted from the manufacturer. Biotinylated goat anti-mouse
IgG and mouse anti-rabbit IgM were used as secondary
antibodies. The DAB was used to visualize the antigens. This
was followed by application of liquid diaminobenzidine and
substrate-chromogen, yielding a brown reaction product at the
site of the target antigen. Finally, slides were counterstained with
hematoxylin to visualize the nuclei. For each antibody, including
negative controls, all TMA staining was performed in a single
experiment.
Scoring of IHC
The ARIOL imaging system (Genetix, San Jose, CA) was used
to scan the slides for antibody staining of the TMAs. The
specimens were scanned at a low resolution (1.256) and high
resolution (206) using an Olympus BX 61 microscope with an
automated platform (Prior). The slides were loaded in the
automated slide loader (Applied Imaging SL 50). Representative
and viable tissue sections were scored manually on a computer
screen semi-quantitatively for cytoplasmic staining. Tumors were
scored as 0 (no cells), 1 (1–5 cells), 2 (6–19 cells) or 3 (20+ cells)
(Figure 1). All samples were made anonymous and independently
scored by two pathologists (AV and SWS). Where there was
disagreement, the slides were re-examined and a consensus was
reached by the observers. When assessing a variable for a given
score, the scores of the other variables and the outcome were
hidden from the observers.
Statistical Methods
All statistical analyses were done using the statistical package
SPSS (Chicago, IL), version 16. The immunohistochemistry scores
from each observer were compared for interobserver reliability by
use of a two-way random effect model with absolute agreement
definition. The intraclass correlation coefficient (reliability coeffi-
cient) was obtained from these results.
The Chi-square test and Fishers Exact test were used to
examine the association between molecular marker expression and
various clinicopathological parameters. Univariate analyses were
done using the Kaplan-Meier method, and statistical significance
between survival curves was assessed by the log rank test. Disease-
specific survival (DSS) was determined from the date of
histological-confirmed STS diagnosis.
Multivariate analysis was carried out using the Cox proportional
hazards model to assess the specific impact of each pre-treatment
variable on survival in the presence of other variables. Only
variables of significant value from the univariate analysis were
entered into the Cox regression analysis. Probability for stepwise
entry and removal was set at 0.05 and 0.10, respectively. The
significance level used was p,0.05.
Results
Clinicopathological Variables
Demographic, clinical, and histopathological variables are
shown in Table 1. Patient age range was 0–91 years (mean 55
years), and 44% of the patients were males. The non-GIST STS
comprised 68 undifferentiated pleomorphic sarcoma, 67 leiomyo-
sarcoma, 34 liposarcoma, 20 malignant fibroblastic/myofibroblas-
tic tumors, 16 rhabdomyosarcoma, 16 synovial sarcoma, 13
angiosarcoma, 11 malignant peripheral nerve sheath tumors
(MPNST) and 4 other STS. There were 61 low grade STS
(24%) and 188 high grade (FNCLCC grade 2 and 3) STS (76%).
Characteristic
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%) P
Non-wide 141 57 19 33
Chemotherapy
No 191 77 52 47 0.424
Yes 58 23 29 40
Radiotherapy
No 176 71 48 46 0.590
Yes 73 29 38 43
Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; STS, soft tissue sarcomas; NR, not reached;
NOS, non specified.
doi:10.1371/journal.pone.0014611.t001
Table 1. Cont.
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patients received surgery only; 55 patients received surgery and
radiotherapy; 40 patients received surgery and chemotherapy; 13
patients received surgery, radiotherapy and chemotherapy; 2
patients received chemotherapy only; 3 patients received chemo-
therapy and radiotherapy; 2 patients received radiotherapy only;
and16 patients received no therapy. The 5-year survival with non-
wide resection margins was 33% and with wide resection margins
it was 62%.
Inter-observer variability
There was good reproducibility between the two investigating
pathologists. Their scoring agreement was tested for CD8 and
CD20. The IHC scores from each observer were compared using
a two-way random effect model with absolute agreement
definition. The intra-class correlation coefficients (reliability
coefficients, r) obtained from these results were 0.90 for CD8
(P,0.001) and 0.90 for CD20 (P,0.001).
Univariate analyses
Nationality, tumor size, malignancy grade, tumor depth,
metastasis at time of diagnosis, surgery and surgical margins were
all significant indicators for disease-specific survival (DSS) in
univariate analyses (Table 1, Figure 2). Most of the patients with
non-GIST STS who did not survive their disease, died within the
first 10 years (120 months). After 10 years almost 60% (n=108) of
the patients with wide resection margins were alive, but only 20%
(n=141) of patients with non-wide resection margins or no surgery
(P,0.001), (Figure 2).
Furthermore, increasing numbers of CD4+ (P=0.008) and
CD20+ lymphocytes in tumor (P=0.006) correlated significantly
Table 2. Intratumoral lymphocyte infiltration and their prediction for disease-specific survival in patients with soft tissue sarcomas
(univariate analysis; log-rank test), N=249.
Non-wide resections margins, n=141 Wide resection margins, n=108
Marker expression
Patients
(n)
Patients
(%)
Median
survival
(months)
5-Year
survival
(%) P
Patients
(n)
Patients
(%)
Median
survival
(months)
5-Year
survival
(%) P
CD 3
Low 95 67 26 39 0.028 81 75 NR 64 0.983
High 26 18 15 28 19 18 NR 61
Missing 20 14 8 7
CD 4
Low 112 79 23 35 0.474 85 79 NR 57 0.008
High 18 13 12 33 16 15 NR 94
Missing 11 8 7 6
CD 8
Low 98 70 22 37 0.349 85 79 NR 61 0.150
High 21 15 26 29 19 18 NR 79
Missing 22 16 4 4
CD 20
Low 103 73 26 34 0.447 83 77 NR 55 0.006
High 20 14 11 35 22 20 NR 86
Missing 18 13 3 3
CD 45
Low 113 80 21 33 0.745 87 81 NR 61 0.530
High 19 13 25 37 18 17 NR 67
Missing 9 6 3 3
Abbreviations: NR, not reached.
doi:10.1371/journal.pone.0014611.t002
Figure 2. Disease-specific survival curves for patients with
wide resection margins compared to patients with non-wide
resection margins.
doi:10.1371/journal.pone.0014611.g002
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margins.
doi:10.1371/journal.pone.0014611.g003
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(n=108), (Table 2 and Figure 3). No such relationship was
apparent for CD3+, CD8+ and CD45+ lymphocytes. In patients
with non-wide resection margins (n=141) increasing numbers of
CD3+ lymphocytes correlated significantly (P=0.028) with shorter
DSS, (Table 2).
Improved survival was seen in patients younger than 60 years
(P=0.005), in tumors of histological grade 1 and 2 (P=0.011), in
tumors less than 5 cm (P=0.018) and in patients who received
chemotherapy (P=0.024). This was shown through subgroup
analysis of patients with high CD20+ lymphocytes in tumor and
wide resection margins, Table 3. The same statistical trend was
seen for gender, nationality, histology, tumor localization and in
patients with or without radiotherapy, but these were not
statistically significant (data not shown). There were no significant
differences in the expression of the different immunomarkers in
the different tumor groups (data not shown).
Multivariate analyses
Significant demographic, clinicopathological, and lymphocyte
infiltrate variables from the univariate analyses were entered into
the multivariate Cox regression analysis. An independent positive
prognostic factor for improved DSS in patients with wide resection
margin was a high number of CD20+ lymphocytes in the tumor
(HR 5.5, CI 95% 1.62–18.61, P=0.006).
Independent negative prognostic variables were Russian
nationality (P=0.020), high malignancy grade (P=0.016) and
metastasis at time of diagnosis (P=0.001, Table 4). In patients
with non-wide resection margins (n=141) increasing numbers of
CD3+ lymphocytes was an independent negative prognostic factor
for DSS, (HR 2.2, CI 95% 1.25–3.89, P=0.007), (Table 4).
Discussion
In this large scale study, we evaluated whether there is an
association between the prevalence of CD3+, CD4+, CD8+,
CD20+ and CD45+ lymphocytes in tumors and survival prognosis
in 249 non-GIST STS patients. Interestingly, high intensities of
CD20+ cells in tumors were an independent positive prognostic
factor in patients with wide resection margins.
To our knowledge, this is the first report on CD20 expression in
non-GIST STS and the first evidence of its possible clinical
Table 3. Results of subgroup analysis of patients with CD20+ lymphocytes in tumor and wide resection margins, n=108.
Subgroup
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%) P
Age
,60, CD20 Low 49 79 - 56 0.005
,60, CD20 High 11 18 -* 100
Missing 2 3
.60, CD20 Low 34 74 NR 54 0.347
.60, CD20 High 11 24 NR 73
Missing 1 2
Histological grade
1 or 2, CD20 Low 52 76 - 67 0.011
1 or 2, CD20 High 14 21 - 100
Missing 2 3
3, CD20 Low 31 78 28 34 0.155
3, CD20 High 8 20 NR 63
Missing 1 3
Tumor size
,5 cm, CD20 Low 28 70 - 63 0.018
,5 cm, CD20 High 10 25 - 100
Missing 2 5
.5 cm, CD20 Low 53 78 63 52 0.169
.5 cm, CD20 High 12 18 NR 75
Missing 3 4
Chemotherapy
Yes, CD20 Low 24 80 - 82 0.024
Yes, CD20 High 5 17 - 100
Missing 1 3
No, CD20 Low 59 76 NR 59 0.080
No, CD20 High 17 22 NR 46
Missing 2 3
* Median survival is not computed because all cases are censored.
Abbreviations: NR, not reached.
doi:10.1371/journal.pone.0014611.t003
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This may suggest that CD20+ cells in the tumor are mediating a
strong anti-tumor immune response in STS, but this effect is not
strong enough to improve survival in patients without wide
resection margins.
Activation of the adaptive immune system may suppress
malignant cells, whereas activation of various types of innate
immune cells may promote tumor growth[14]. The adaptive
immunity, orchestrated by antigen-specific T and B-lymphocytes,
inhibits tumor growth through both direct killing by cytotoxic T-
lymphocytes, and a combination of cytokine and antibody
mediated tumor cell lysis[14]. Cancer infiltration by tumor
reactive T-lymphocytes is required for efficient tumor eradica-
tion[15]. However, cancer cells can escape the immune system in
several ways including suppression of cytotoxic T-cells, by
regulatory T-cells and by accumulation of myeloid suppressor
cells[15–17].
Tumor-infiltration CD3+ cells are reported to be strongly
associated with favorable prognosis in epithelial tumors in several
studies[18–22]. The CD3+ cell is an independent positive
predictor of response to neoadjuvant chemotherapy in breast
cancer[23]. Low numbers of CD3+ lymphocytes predicted shorter
disease-free survival in colon cancer[24] and cervical cancers[25].
However, T-cell parameters including CD3 values showed no
correlation with survival in cases of metastatic ovarian carcino-
ma[26]. Accordingly, we did not find any such association in our
mesenchymal material in patients with wide resection margins, but
CD3 was a negative prognostic factor in patients with non-wide
resection margins.
The role of CD4+ T and B lymphocytes is controversial in
many cancers including STS; CD4+ cells in the absence of the
CD8+ cytotoxic T cells are critical and sufficient for NKT cell-
dependent rejection of experimental tumours[27]. In lung cancer
the prognostic impact of CD4 is controversial[28,29], but in our
material CD4+ cells were a positive prognostic factor in univariate
analyses.
CD8+ cells in malignant tumors have been associated with a
better survival in many types of cancer including: non-small cell
lung carcinoma; carcinomas of the endometrium, bile duct, colon,
oesophagus, urothelium; and uveal melanoma and follicular
lymphoma[28,30–37]. However, the role of CD8+ lymphocytes
in STS is controversial and most of the studies contain relatively
few cases. There was a positive correlation between a high density
of CD4+ and CD8+ lymphocytes in stroma and improved disease-
specific survival in non-small cell lung cancer[28]. In our material
CD8 was not a statistically significant factor (P=0.15).
CD20+ cells are associated with a better survival in lung cancer,
cervical cancer, prostate cancer and ovarian cancer[25,28,38–40].
CD20+ B-cells in metastatic lymph nodes are associated with
favourable outcome in patients with oro- and hypopharyngeal
Table 4. Results of Cox regression analysis summarizing some significant independent prognostic factors in patients with soft
tissue sarcomas, N=249.
Non-wide resections margins, n=141 Wide resection margins, n=108
Factor Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Nationality
Norwegian 1.000 1.000
Russian 1.635 0.978–2.731 0.061 2.246 1.135–4.444 0.020
Tumor size 0.428* 0.874*
#5 cm 1.000 1.000
5–10 cm 0.826 0.463–1.605 1.217 0.547–2.708
.10 cm 1.232 0.690–2.199 1.045 0.389–2.806
Malignancy grade FNCLCC 0.024* 0.016*
1 1.000 1.000
2 1.237 0.611–2.506 3.464 1.081–11.096 0.036
3 2.214 1.108–4.425 5.046 1.656–15.376 0.004
Metastasis at time of diagnosis
No 1.000 1.000
Yes 3.651 2.081–6.409 ,0.001 3.872 1.696–8.836 0.001
CD3
Low 1.000 NIA
High 2.202 1.245–3.893 0.007
CD4
Low NIA 4.126 0.551–30.895 0.168
High 1.000
CD20
Low NIA 5.503 1.627–18.606 0.006
High 1.000
* Overall significance as a prognostic factor.
Abbreviations: NIA, not included in analysis.
doi:10.1371/journal.pone.0014611.t004
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flowcytometry with CD19 were correlated with unfavourable
outcome in metastatic ovarian carcinoma[26]. In our material
high density of CD20+ lymphocytes was an independent positive
prognostic indicator.
In cervical cancer no significant impact of CD45+ cells were
seen [25], neither was it in non-GIST STS in this study.
The optimal chance for curing localized STS is based on wide
resection surgery. Given that of the majority of STS patients
succumb to this disease within 5 years, there is an apparent need
for better systemic therapy including novel molecularly targeted
therapies[42]. In our study, there was a 33% 5-year survival in the
group with non-wide resection margins and 62% of those with
wide resection margins.
Among STS patients who have had wide resection margins, it
will be essential to identify those who will relapse and succumb this
disease as these patients may benefit from adjuvant therapy,
including immunotherapy. Until now adjuvant chemotherapy has
been controversial due to inadequate selection criteria.
The human immune system contains specialized cells that are
able to eliminate cancer cells[26], and tumor-infiltrating B-
cells are able to produce tumor-specific antibodies[43]. Through
external stimulation of the immune response, these cells may have
the potential to aid the immune system in destroying single tumor
cells and micro-metastases after surgery. This topic is investigated
in the ongoing international osteosarcoma protocol EURAMOS
where those who respond well to chemotherapy are randomized to
receive interferon or no interferon, in an attempt to improve the
immune response (http://www.ctu.mrc.ac.uk/euramos/).
In conclusion, high density of CD20+ lymphocytes in STS with
wide resection margins is an independent positive prognostic
indicator for these patients. Further research to define if CD20+
cells can modify tumors in a way that reduces disease progression
and metastatic potential is needed.
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